K
5.67
-0.18 (-3.08%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kyverna Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.04 |
Select this tab to load the latest available analysis.
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 12.04% |
| % Held by Institutions | 68.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gordonmd Global Investments Lp | 30 Jun 2026 | 4,244,818 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 4,126,119 |
| Aigh Capital Management Llc | 30 Jun 2026 | 2,795,797 |
| Insight Holdings Group, Llc | 30 Jun 2026 | 989,054 |
| Propel Bio Management, Llc | 30 Jun 2026 | 883,198 |
| Woodline Partners Lp | 30 Jun 2026 | 845,325 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |